Oncotelic to Attend BIO International 2024 Meeting

AGOURA HILLS, Calif., May 30, 2024 - Oncotelic Therapeutics, Inc. (OTCQB:OTLC) has announced that its CEO, Dr. Vuong Trieu, will participate in the BIO International 2024 meeting, scheduled from June 3-6 in San Diego. The BIO International Convention is the preeminent event in the biotechnology sector, gathering over 18,500 industry leaders from around the world to discuss the latest advancements and trends in biotech.

About Oncotelic Therapeutics

Oncotelic Therapeutics, formerly known as Mateon Therapeutics, Inc., has a rich history dating back to its establishment in New York in 1988 as OXiGENE, Inc. The company reincorporated in Delaware in 1992, rebranded as Mateon Therapeutics in 2016, and finally adopted its current name in November 2020. Oncotelic is committed to harnessing its extensive expertise in oncology drug development with a particular focus on improving outcomes and survival rates for cancer patients, especially those with rare pediatric cancers.

The company's drug portfolio includes OT-101 for Diffuse Intrinsic Pontine Glioma (DIPG), through a 45% joint venture with GMP Biotechnology Limited, CA4P for melanoma, and OXi 4503 for Acute Myeloid Leukemia. Additionally, Oncotelic expanded its capabilities by acquiring PointR Data Inc. in November 2019 to foster the development of an AI-driven biotechnology platform.

In the fourth quarter of 2021, Oncotelic acquired AL-101 for the intranasal delivery of apomorphine. The company plans to develop AL-101 for treating Parkinson's disease, erectile dysfunction, female sexual disorder, and hypoactive sexual desire disorder. These conditions affect a significant number of people, underscoring the need for effective treatments. For detailed information on AL-101, refer to Oncotelic’s Annual Report on Form 10-K/A filed with the SEC on April 19, 2023.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!